 Valneva SEs NASDAQ: VALN COVID-19 vaccine elicits a robust immune response with far fewer side effects than the OxfordAstraZeneca plcs NASDAQ: AZN jab, according to Phase 3 trial results. Valneva said its latest trial, Cov-Compare, included around 4,000 participants aged 18 and older across 26 trial sites. 